CLRB Share Price Performance
US$2.55
-4.87 (-65.63%)
96.6% undervalued intrinsic discount
US$76.00
Fair Value
Price US$2.55
AnalystConsensusTarget US$76.00
AnalystLowTarget US$10.00
AnalystHighTarget US$76.00
Fair ValueUS$76.00
Share Pricen/a
Cellectar Biosciences, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
CLRB Community Narratives
AN
Fair Value US$76 96.6% undervalued intrinsic discount
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$10 74.5% undervalued intrinsic discount
Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$76 96.6% undervalued intrinsic discount
Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects
Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies based on its phospholipid drug conjugate platform for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$76
96.6% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
40.23x
Price in 2029
US$0
Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve
Catalysts About Cellectar Biosciences Cellectar Biosciences is a radiopharmaceutical company focused on phospholipid drug conjugates for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$10
74.5% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
24.92x
Price in 2029
US$0
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies for difficult to treat cancers using its proprietary phospholipid drug conjugate platform. What are the underlying business or industry changes driving this perspective?Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$76
96.6% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
185.57x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects
Fair Value: US$76 96.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve
Fair Value: US$10 74.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
Fair Value: US$76 96.6% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cellectar Biosciences, Inc. Key Details
About CLRB
- Founded
- 2002
- Employees
- 11
- CEO
- WebsiteView website
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Recent CLRB News & Updates
